Pacific Biosciences of California, Inc. Q1 2026 Earnings Recap

Shares dropped 14.5% following earnings as the market reacted to weaker-than-expected instrument revenue, particularly from the Vega system, driven by continued academic funding pressure and regional challenges, signaling concerns about deceleration and margin pressure.

Key Takeaways

• Instrument revenue fell short of expectations; Vega shipments declined slightly (27 vs. 28 units year-over-year) with promotional pricing compressing average selling prices.
• Revio system shipments increased modestly to 15 units from 12 a year ago, but ongoing funding constraints in the Americas limited growth.
• Consumable revenue grew 9% year-over-year, supported by over 100% shipment growth to clinically focused accounts, partially offset by customer delays awaiting SPRQ-Nx launch.
• Geographic performance was mixed: strong 17% revenue growth in EMEA contrasted with a 16% decline in Asia Pacific due to delayed SPRQ-Nx kit shipments.
• Management highlighted optimism for SPRQ-Nx chemistry driving future system and consumable demand, but cautious near-term outlook reflected by continued soft instrument demand and external headwinds.